The ESA Disconnect Between FDA and CMS
This article was originally published in RPM Report
Executive Summary
Another major decision is looming at CMS on whether to open up a national coverage analysis for ESAs in the renal disease area-a MEDCAC meeting appears to be the first step. The Medicare agency previously jumped out in front of FDA on a coverage decision in the oncology setting. This time, it appears that CMS will wait to hear what FDA has to say. But FDA isn't paying much attention to CMS.